[Lymphatic involvement predominating and revealing prostatic carcinoma].
Identifieur interne : 001975 ( Ncbi/Curation ); précédent : 001974; suivant : 001976[Lymphatic involvement predominating and revealing prostatic carcinoma].
Auteurs : R. Llarena Ibarguren [Espagne] ; J A Zabala Egurrola ; A. Arruza Echevarría ; P. Arregui Erbina ; C. Pertusa Pe ASource :
- Archivos espanoles de urologia [ 0004-0614 ] ; 1992.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Adénocarcinome (), Adénocarcinome (anatomopathologie), Adénocarcinome (diagnostic), Association thérapeutique, Humains, Lymphoedème (étiologie), Mâle, Métastase lymphatique (imagerie diagnostique), Pronostic, Sujet âgé, Tomodensitométrie, Tumeurs de la prostate (), Tumeurs de la prostate (anatomopathologie), Tumeurs de la prostate (diagnostic).
- MESH :
- anatomopathologie : Adénocarcinome, Tumeurs de la prostate.
- diagnostic : Adénocarcinome, Tumeurs de la prostate.
- imagerie diagnostique : Métastase lymphatique.
- étiologie : Lymphoedème.
- Adulte d'âge moyen, Adénocarcinome, Association thérapeutique, Humains, Mâle, Pronostic, Sujet âgé, Tomodensitométrie, Tumeurs de la prostate.
English descriptors
- KwdEn :
- Adenocarcinoma (diagnosis), Adenocarcinoma (pathology), Adenocarcinoma (therapy), Aged, Combined Modality Therapy, Humans, Lymphatic Metastasis (diagnostic imaging), Lymphedema (etiology), Male, Middle Aged, Prognosis, Prostatic Neoplasms (diagnosis), Prostatic Neoplasms (pathology), Prostatic Neoplasms (therapy), Tomography, X-Ray Computed.
- MESH :
- diagnosis : Adenocarcinoma, Prostatic Neoplasms.
- diagnostic imaging : Lymphatic Metastasis.
- etiology : Lymphedema.
- pathology : Adenocarcinoma, Prostatic Neoplasms.
- therapy : Adenocarcinoma, Prostatic Neoplasms.
- Aged, Combined Modality Therapy, Humans, Male, Middle Aged, Prognosis, Tomography, X-Ray Computed.
Abstract
The lymphatic system is the most common site of metastasis of prostatic carcinoma. However, carcinoma of the prostate presenting as lymphadenopathy is rare. It can present at any site and may sometimes mimic lymphoreticular tumors. The diagnosis is based on the histological findings. Histochemical techniques using immunoperoxidase demonstration of acid phosphatase and prostate specific antigen are fundamental in detecting the occult tumor of the prostate. Treatment is palliative and enlargement may occasionally remit with hormone therapy. The prognosis is invariably poor. Survival is less than 5 years irrespective of the response to treatment. Three cases are described herein: 2 presented as retroperitoneal mass and 1 as left lateral cervical lymphadenopathy.
PubMed: 1510479
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005932
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :005932
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :005932
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001975
Links to Exploration step
pubmed:1510479Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Lymphatic involvement predominating and revealing prostatic carcinoma].</title><author><name sortKey="Llarena Ibarguren, R" sort="Llarena Ibarguren, R" uniqKey="Llarena Ibarguren R" first="R" last="Llarena Ibarguren">R. Llarena Ibarguren</name><affiliation wicri:level="1"><nlm:affiliation>Servicio de Urología, Hospital de Cruces, Vizcaya, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Urología, Hospital de Cruces, Vizcaya</wicri:regionArea><wicri:noRegion>Vizcaya</wicri:noRegion></affiliation></author><author><name sortKey="Zabala Egurrola, J A" sort="Zabala Egurrola, J A" uniqKey="Zabala Egurrola J" first="J A" last="Zabala Egurrola">J A Zabala Egurrola</name></author><author><name sortKey="Arruza Echevarria, A" sort="Arruza Echevarria, A" uniqKey="Arruza Echevarria A" first="A" last="Arruza Echevarría">A. Arruza Echevarría</name></author><author><name sortKey="Arregui Erbina, P" sort="Arregui Erbina, P" uniqKey="Arregui Erbina P" first="P" last="Arregui Erbina">P. Arregui Erbina</name></author><author><name sortKey="Pertusa Pe A, C" sort="Pertusa Pe A, C" uniqKey="Pertusa Pe A C" first="C" last="Pertusa Pe A">C. Pertusa Pe A</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1510479</idno><idno type="pmid">1510479</idno><idno type="wicri:Area/PubMed/Corpus">005932</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005932</idno><idno type="wicri:Area/PubMed/Curation">005932</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005932</idno><idno type="wicri:Area/PubMed/Checkpoint">005932</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005932</idno><idno type="wicri:Area/Ncbi/Merge">001975</idno><idno type="wicri:Area/Ncbi/Curation">001975</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Lymphatic involvement predominating and revealing prostatic carcinoma].</title><author><name sortKey="Llarena Ibarguren, R" sort="Llarena Ibarguren, R" uniqKey="Llarena Ibarguren R" first="R" last="Llarena Ibarguren">R. Llarena Ibarguren</name><affiliation wicri:level="1"><nlm:affiliation>Servicio de Urología, Hospital de Cruces, Vizcaya, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Urología, Hospital de Cruces, Vizcaya</wicri:regionArea><wicri:noRegion>Vizcaya</wicri:noRegion></affiliation></author><author><name sortKey="Zabala Egurrola, J A" sort="Zabala Egurrola, J A" uniqKey="Zabala Egurrola J" first="J A" last="Zabala Egurrola">J A Zabala Egurrola</name></author><author><name sortKey="Arruza Echevarria, A" sort="Arruza Echevarria, A" uniqKey="Arruza Echevarria A" first="A" last="Arruza Echevarría">A. Arruza Echevarría</name></author><author><name sortKey="Arregui Erbina, P" sort="Arregui Erbina, P" uniqKey="Arregui Erbina P" first="P" last="Arregui Erbina">P. Arregui Erbina</name></author><author><name sortKey="Pertusa Pe A, C" sort="Pertusa Pe A, C" uniqKey="Pertusa Pe A C" first="C" last="Pertusa Pe A">C. Pertusa Pe A</name></author></analytic><series><title level="j">Archivos espanoles de urologia</title><idno type="ISSN">0004-0614</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (diagnosis)</term><term>Adenocarcinoma (pathology)</term><term>Adenocarcinoma (therapy)</term><term>Aged</term><term>Combined Modality Therapy</term><term>Humans</term><term>Lymphatic Metastasis (diagnostic imaging)</term><term>Lymphedema (etiology)</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Prostatic Neoplasms (diagnosis)</term><term>Prostatic Neoplasms (pathology)</term><term>Prostatic Neoplasms (therapy)</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Adénocarcinome ()</term><term>Adénocarcinome (anatomopathologie)</term><term>Adénocarcinome (diagnostic)</term><term>Association thérapeutique</term><term>Humains</term><term>Lymphoedème (étiologie)</term><term>Mâle</term><term>Métastase lymphatique (imagerie diagnostique)</term><term>Pronostic</term><term>Sujet âgé</term><term>Tomodensitométrie</term><term>Tumeurs de la prostate ()</term><term>Tumeurs de la prostate (anatomopathologie)</term><term>Tumeurs de la prostate (diagnostic)</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Adenocarcinoma</term><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Lymphatic Metastasis</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Métastase lymphatique</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Adenocarcinoma</term><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Combined Modality Therapy</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Adénocarcinome</term><term>Association thérapeutique</term><term>Humains</term><term>Mâle</term><term>Pronostic</term><term>Sujet âgé</term><term>Tomodensitométrie</term><term>Tumeurs de la prostate</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The lymphatic system is the most common site of metastasis of prostatic carcinoma. However, carcinoma of the prostate presenting as lymphadenopathy is rare. It can present at any site and may sometimes mimic lymphoreticular tumors. The diagnosis is based on the histological findings. Histochemical techniques using immunoperoxidase demonstration of acid phosphatase and prostate specific antigen are fundamental in detecting the occult tumor of the prostate. Treatment is palliative and enlargement may occasionally remit with hormone therapy. The prognosis is invariably poor. Survival is less than 5 years irrespective of the response to treatment. Three cases are described herein: 2 presented as retroperitoneal mass and 1 as left lateral cervical lymphadenopathy.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001975 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001975 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:1510479
|texte= [Lymphatic involvement predominating and revealing prostatic carcinoma].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:1510479" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |